secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2024-07-01T23:59:59+00:00
Accession:  0001628280-24-030546
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid/Graviton announce positive Phase 1 data for OV888/GV101 CCM therapy; Phase 2 expected H2 2024
--------------------------------------------------------------------------------

- Phase 1 met primary safety/tolerability objectives: no serious adverse events at any dose.
- Headache was most common AE (23%); all mild and resolved within 24 hours.
- Target PK achieved: half-life ~12 hours supports once-daily dosing.
- Dose-dependent decrease in proinflammatory cytokines IL-17 and IL-21 confirms ROCK2 target engagement.
- Phase 2 proof-of-concept study in cerebral cavernous malformations planned for second half 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024030546/0001628280-24-030546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024030546/ovid-20240701.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-030546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer